Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Reuters NewMedia, Inc. - Wednesday November 19, 8:49 pm Eastern Time
The U.S. Public Health Service and the International AIDS Society has already used the research as the basis for recommendations that such drugs be immediately given to those with an occupational exposure to the human immunodeficiency virus that causes AIDS.
The risk of contracting HIV can be cut by up to 80 percent if the immediate treatment with AZT is given, researchers said in the study published in Thursday's New England Journal of Medicine.
British-based Glaxo Wellcome Plc (GLXO.L) makes AZT.
The results do not definitively prove that immediate AZT treatment cuts the risk of AIDS. But now the evidence "is far more convincing," said Dr. David Henderson of the National Institutes of Health Clinical Center in Bethesda.
A team led by Dr. Denise M. Cardo of the Centers for Disease Control and Prevention in Atlanta based their 80 percent estimate on the cases of 33 health care workers who contracted the AIDS virus and 665 who did not after they were exposed to contaminated blood on the job.
The 698 people were from the United States, Italy, France and the United Kingdom.
The Cardo team found the risk of developing HIV was higher if the cut was deeper or blood was visible on the instrument that caused the cut.
The immediate treatment was not successful in all cases.
"At least 13 instances of failure of postexposure prophylaxis with (AZT) in health care workers have been documented worldwide, indicating that any protection provided is not absolute," Cardo and her colleagues said.
971119
RE971110
Copyright © 1997 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .